2011
DOI: 10.1016/j.tripleo.2010.09.065
|View full text |Cite
|
Sign up to set email alerts
|

Effects of bone morphogenetic protein 2 gene therapy on new bone formation during mandibular distraction osteogenesis at rapid rate in rabbits

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
25
1

Year Published

2012
2012
2018
2018

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 31 publications
(26 citation statements)
references
References 23 publications
0
25
1
Order By: Relevance
“…To provide a sustained and prolonged release of BMPs, several options are currently being investigated: gene therapy, cell therapy, multiple repeated injections of rhBMPs or cytokine therapy. Gene therapy is still in the experimental stages of research (Long et al, 2011). Multiple repeated injections of rhBMPs are not an option from a practical point of view.…”
Section: Issues Associated With the Use Of Large Doses Of Bmps In Thementioning
confidence: 99%
“…To provide a sustained and prolonged release of BMPs, several options are currently being investigated: gene therapy, cell therapy, multiple repeated injections of rhBMPs or cytokine therapy. Gene therapy is still in the experimental stages of research (Long et al, 2011). Multiple repeated injections of rhBMPs are not an option from a practical point of view.…”
Section: Issues Associated With the Use Of Large Doses Of Bmps In Thementioning
confidence: 99%
“…In both long bone [15]–[18] and mandibular DO studies [19][21], to date the most commonly used method of cell delivery is direct injection of MSCs carried by platelet rich plasma, saline or collagen gel. While an injection method sounds straightforward, the difficulty involved in delivering the cells to the desired locations of a closed subcutaneous bone site cannot be overestimated.…”
Section: Introductionmentioning
confidence: 99%
“…14 Some researchers have also used mesenchymal stem cell-based gene therapy to continuously release BMP-2 during the distraction and consolidation periods in an effort to maximize bone regeneration. 25 However, gene therapy has historically been difficult to use clinically due to unpredictable expression, variability in the effective period, complexity in gene transfection processes, and the unknown hazards of using an adenoviral vector. 26 Fewer studies have been conducted in the TDO model using BMP-2.…”
Section: Discussionmentioning
confidence: 99%